News from norgine A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

11 Jun, 2019, 09:00 BST New Study Shows Rifaximin Significantly Reduced the Number and Length of Hospitalisations in Patients With Overt Hepatic Encephalopathy (HE) Awaiting Liver Transplatation

Rifaximin significantly reduced the incidence of all-cause hospital admissions in HE patients with advanced cirrhosis on the waiting list for liver...


15 Apr, 2019, 09:00 BST Norgine: New Real World Study Shows Rifaximin-a Significantly Reduced Hospitalisation in Patients With Overt Hepatic Encephalopathy (HE) When Added to Lactulose

Norgine B.V. today highlighted results of a real world study showing significant reductions in the number and length of hospitalisations when...


04 Apr, 2019, 13:24 BST Norgine New Study Highlights Need to Increase Public Understanding of Important Role of Colonoscopy in Preventing and Diagnosing Gastrointestinal Diseases, Including Colorectal Cancer

NORGINE B.V. (Norgine) today published the findings of a public survey at the European Society of Gastrointestinal Endoscopy (ESGE) Days in Prague as ...


04 Mar, 2019, 12:08 GMT Important New Trial With Oral FERACCRU® Shows Comparable Efficacy to IV Iron (Ferric Carboxymaltose), Offering a Real Alternative to Hospital Administration for Many Patients[4]

FERACCRU® (Ferric Maltol) met primary endpoint against Ferinject® (IV Ferric Carboxymaltose (FCM)) and shows clear benefits to Iron Deficiency...


05 Dec, 2018, 09:00 GMT Feraccru®, a Novel, Effective and Well Tolerated Treatment for Iron Deficiency Launched in the UK by Norgine

Feraccru®, a novel, effective and well tolerated treatment for iron deficiency (ID) with or without anaemia including treatment of iron deficiency...


24 May, 2013, 11:00 BST PBAC Approves XIFAXAN® (Rifaxamin α) 550 mg Cost Effectiveness in Australia

Norgine today announced that the Australian assessment body the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the use of XIFAXAN...


18 Dec, 2012, 07:00 GMT Norgine and SpePharm Holding Enter Into Joint Venture

Norgine BV (Amsterdam) and SpePharm Holding BV (Amsterdam) announced today that they have concluded a broad collaboration agreement under which the...